ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer

Rokana Taftaf(Northwestern University), Huiping Liu(Guangxi University), Youbin Zhang(Northwestern University), Erika K. Ramos(Northwestern University), Yue Cao(Oregon State University), Salendra Singh(Case Western Reserve University), Massimo Cristofanilli(Cornell University), William A. Müller(Northwestern University), Yuzhi Jia(Northwestern University), Xia Liu(Shaanxi Research Association for Women and Family), Paolo D’Amico(Ripamonti), Valery Adorno-Cruz(Northwestern University), Carolina Reduzzi(Cornell University), David Scholten(Northwestern University), Emma J. Schuster(Northwestern University), Nurmaa K. Dashzeveg(Northwestern University), Andrew D. Hoffmann(Northwestern University), Yang Shen(Tiangong University), Dhwani Patel(Northwestern University), Vinay Varadan(Case Western Reserve University), Andrew A. Davis(Washington University in St. Louis), Lamiaa El-Shennawy(Northwestern University)
Nature Communications
August 11, 2021
10.1038/s41467-021-25189-z
Cited by 265

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Endocytosis and the recycling of plasma membrane.
|The Journal of Cell Biology|1983|1.5k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
PECAM-1 is required for transendothelial migration of leukocytes.
|The Journal of Experimental Medicine|1993|1.1k